In vitro and in vivo cardioprotective and metabolic efficacy of vitamin E TPGS/Apelin. (January 2020)
- Record Type:
- Journal Article
- Title:
- In vitro and in vivo cardioprotective and metabolic efficacy of vitamin E TPGS/Apelin. (January 2020)
- Main Title:
- In vitro and in vivo cardioprotective and metabolic efficacy of vitamin E TPGS/Apelin
- Authors:
- Leme Goto, Patricia
Cinato, Mathieu
Merachli, Fadi
Vons, Bohdana
Jimenez, Tony
Marsal, Dimitri
Todua, Nika
Loi, Halyna
Santin, Yohan
Cassel, Stéphanie
Blanzat, Muriel
Tronchere, Helene
Dejugnat, Christophe
Kunduzova, Oksana
Boal, Frederic - Abstract:
- Abstract: Aims: Apelin and vitamin E have been proposed as signaling molecules, but their synergistic role is unknown. The aim of this work was to develop vitamin E TPGS/Apelin system to test their cardioprotective and metabolic efficacy in vitro and in vivo. Methods: FDA-approved surfactant D-α-tocopheryl polyethylene glycol 1000 succinate (TPGS-1000) and Apelin complex were characterized by physico-chemical methods (CMC determination, dynamic light scattering and circular dichroism). In vitro studies were carried out on H9C2 cardiomyoblasts and isolated murine cardiomyocytes. In vivo studies were performed in isoproterenol- and high-fat diet-induced cardiac remodeling models in mice. Results: We found that vitamin E TPGS/Apelin provide cardioprotective and metabolic efficacy in vitro and in vivo. In vitro studies revealed that vitamin E TPGS/Apelin reduces hypoxia-induced mitochondrial ROS production in cultured cardiomyocytes and H9C2 cardiomyoblasts. In addition, vitamin E TPGS/Apelin confers apoptotic response to hypoxic stress in cells. In a mouse model of isoproterenol - induced cardiac injury, TPGS is not able to affect cardiac remodeling, however combination of vitamin E TPGS and Apelin counteracts myocardial apoptosis, oxidative stress, hypertrophy and fibrosis. Furthermore, combination treatment attenuated obesity-induced cardiometabolic and fibrotic remodeling in mice. Conclusion: Together, our data demonstrated the therapeutic benefits of vitamin E TPGS/ApelinAbstract: Aims: Apelin and vitamin E have been proposed as signaling molecules, but their synergistic role is unknown. The aim of this work was to develop vitamin E TPGS/Apelin system to test their cardioprotective and metabolic efficacy in vitro and in vivo. Methods: FDA-approved surfactant D-α-tocopheryl polyethylene glycol 1000 succinate (TPGS-1000) and Apelin complex were characterized by physico-chemical methods (CMC determination, dynamic light scattering and circular dichroism). In vitro studies were carried out on H9C2 cardiomyoblasts and isolated murine cardiomyocytes. In vivo studies were performed in isoproterenol- and high-fat diet-induced cardiac remodeling models in mice. Results: We found that vitamin E TPGS/Apelin provide cardioprotective and metabolic efficacy in vitro and in vivo. In vitro studies revealed that vitamin E TPGS/Apelin reduces hypoxia-induced mitochondrial ROS production in cultured cardiomyocytes and H9C2 cardiomyoblasts. In addition, vitamin E TPGS/Apelin confers apoptotic response to hypoxic stress in cells. In a mouse model of isoproterenol - induced cardiac injury, TPGS is not able to affect cardiac remodeling, however combination of vitamin E TPGS and Apelin counteracts myocardial apoptosis, oxidative stress, hypertrophy and fibrosis. Furthermore, combination treatment attenuated obesity-induced cardiometabolic and fibrotic remodeling in mice. Conclusion: Together, our data demonstrated the therapeutic benefits of vitamin E TPGS/Apelin complex to combat cardiovascular and metabolic disorders. Highlights: Combination of TPGS-1000 and Apelin-13 prevents oxidative stress and apoptosis in response to hypoxia in cardiac cells. Apelin-13 but not TPGS-1000 treatment dampens isoproterenol-induced myocardial injury in mice. Combination treatment reduces cardiac apoptosis, oxidative stress and metabolic disorders in obese mice. TPGS-1000/Apelin treatment improves cardiac function in obesity-associated heart failure. … (more)
- Is Part Of:
- Journal of molecular and cellular cardiology. Volume 138(2020)
- Journal:
- Journal of molecular and cellular cardiology
- Issue:
- Volume 138(2020)
- Issue Display:
- Volume 138, Issue 2020 (2020)
- Year:
- 2020
- Volume:
- 138
- Issue:
- 2020
- Issue Sort Value:
- 2020-0138-2020-0000
- Page Start:
- 165
- Page End:
- 174
- Publication Date:
- 2020-01
- Subjects:
- Cardiac hypertrophy -- Obesity -- Oxidative stress -- Surfactant
Cardiology -- Periodicals
Heart Diseases -- Periodicals
Molecular Biology -- Periodicals
Cardiologie -- Périodiques
Cardiology
Electronic journals
Periodicals
616.12 - Journal URLs:
- http://www.sciencedirect.com/science/journal/00222828 ↗
http://www.clinicalkey.com/dura/browse/journalIssue/00222828 ↗
http://www.clinicalkey.com.au/dura/browse/journalIssue/00222828 ↗
http://www.elsevier.com/journals ↗ - DOI:
- 10.1016/j.yjmcc.2019.12.001 ↗
- Languages:
- English
- ISSNs:
- 0022-2828
- Deposit Type:
- Legaldeposit
- View Content:
- Available online (eLD content is only available in our Reading Rooms) ↗
- Physical Locations:
- British Library DSC - 5020.690000
British Library DSC - BLDSS-3PM
British Library HMNTS - ELD Digital store - Ingest File:
- 12916.xml